ORIC PHARMACEUTICALS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $679.00K, a 10.30% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $757.00K, a 44.74% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $523.00K, a 30.75% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $400.00K, a 12.99% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.31M, a 21.13% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.08M, a 31.23% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $826.00K, a 51.56% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $545.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $679.00K 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $1.31M 10-K · filed 2026-02-23 | |
| 2025-06-30 | $757.00K 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $1.08M 10-K · filed 2026-02-23 | |
| 2024-06-30 | $523.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $826.00K 10-K · filed 2025-02-18 | |
| 2023-06-30 | $400.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $545.00K 10-K · filed 2024-03-11 | |
| 2022-06-30 | $354.00K 10-Q · filed 2023-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |